Follow
Paolo Caimi
Paolo Caimi
Verified email at ccf.org
Title
Cited by
Cited by
Year
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
14562020
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
AS LaCasce, RG Bociek, A Sawas, P Caimi, E Agura, J Matous, ...
Blood, The Journal of the American Society of Hematology 132 (1), 40-48, 2018
1762018
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ...
Annals of Oncology 32 (6), 787-800, 2021
1582021
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
PF Caimi, W Ai, JP Alderuccio, KM Ardeshna, M Hamadani, B Hess, ...
The Lancet Oncology 22 (6), 790-800, 2021
1532021
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC …
K Dunleavy, MA Fanale, JS Abramson, A Noy, PF Caimi, S Pittaluga, ...
The Lancet Haematology 5 (12), e609-e617, 2018
1242018
NCCN guidelines insights: B-cell lymphomas, version 3.2019: featured updates to the NCCN guidelines
AD Zelenetz, LI Gordon, JS Abramson, RH Advani, NL Bartlett, PF Caimi, ...
Journal of the National Comprehensive Cancer Network 17 (6), 650-661, 2019
1182019
Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19
MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ...
JAMA oncology 7 (8), 1167-1175, 2021
1102021
The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design
KT Flaherty, R Gray, A Chen, S Li, D Patton, SR Hamilton, PM Williams, ...
JNCI: Journal of the National Cancer Institute 112 (10), 1021-1029, 2020
952020
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
M Hamadani, J Radford, C Carlo-Stella, PF Caimi, E Reid, OA O’Connor, ...
Blood 137 (19), 2634-2645, 2021
852021
Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma
AS LaCasce, G Bociek, A Sawas, PF Caimi, E Agura, J Matous, S Ansell, ...
Blood 126 (23), 3982, 2015
782015
Preliminary report of a multicenter prospective phase II study of DA-EPOCH-R in MYC-rearranged aggressive B-cell lymphoma
K Dunleavy, M Fanale, A LaCasce, A Noy, P Caimi, S Parekh, JW Hayslip, ...
Blood, The Journal of the American Society of Hematology 124 (21), 395-395, 2014
742014
Emerging therapeutic approaches for multipotent mesenchymal stromal cells (MSCs)
PF Caimi, J Reese, Z Lee, HM Lazarus
Current opinion in hematology 17 (6), 505, 2010
742010
Gray zone lymphoma with features intermediate between classical H odgkin lymphoma and diffuse large B‐cell lymphoma: C haracteristics, outcomes, and prognostication among a …
AM Evens, JA Kanakry, LH Sehn, A Kritharis, T Feldman, A Kroll, ...
American journal of hematology 90 (9), 778-783, 2015
722015
Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia
MW Harr, PF Caimi, KS McColl, F Zhong, SN Patel, PM Barr, ...
Cell Death & Differentiation 17 (9), 1381-1391, 2010
682010
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
NH Fowler, F Samaniego, W Jurczak, N Ghosh, E Derenzini, JA Reeves, ...
American Society of Clinical Oncology (ASCO), 2021
652021
Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era
JN Gerson, E Handorf, D Villa, AS Gerrie, P Chapani, S Li, LJ Medeiros, ...
Journal of Clinical Oncology 37 (6), 471, 2019
652019
NCCN guidelines insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2017
WG Wierda, AD Zelenetz, LI Gordon, JS Abramson, RH Advani, ...
Journal of the National Comprehensive Cancer Network 15 (3), 293-311, 2017
632017
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
A Forero-Torres, R Ramchandren, A Yacoub, MS Wertheim, WJ Edenfield, ...
Blood, The Journal of the American Society of Hematology 133 (16), 1742-1752, 2019
622019
A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaPhase I …
BS Kahl, M Hamadani, J Radford, C Carlo-Stella, P Caimi, E Reid, ...
Clinical Cancer Research 25 (23), 6986-6994, 2019
582019
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
AM Evens, KR Carson, J Kolesar, C Nabhan, I Helenowski, N Islam, ...
Annals of oncology 24 (12), 3076-3081, 2013
522013
The system can't perform the operation now. Try again later.
Articles 1–20